SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status

The Bcl-2 family of proteins is critical to the life and death of malignant B-lymphocytes. Interfering with their activity using small-molecule inhibitors (SMI) is being explored as a new therapeutic strategy for treating B-cell tumors. We evaluated the efficacy of TW-37, a non-peptidic SMI of Bcl-2...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Katib, Ayad M, Sun, Yuan, Goustin, Anton Scott, Azmi, Asfar Sohail, Chen, Ben, Aboukameel, Amro, Mohammad, Ramzi M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2651908/
https://www.ncbi.nlm.nih.gov/pubmed/19220884
http://dx.doi.org/10.1186/1756-8722-2-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2651908/
https://www.ncbi.nlm.nih.gov/pubmed/19220884
http://dx.doi.org/10.1186/1756-8722-2-8

Ejemplares similares